Brief: Poxel Presents Data For PXL770 And PXL065 For The Treatment of NASH

Poxel SA

12/11/2018 07:17

Nov 12 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL PRESENTS PROMISING DATA FOR PXL770 AND PXL065 FOR
THE
TREATMENT OF NASH AT THE AMERICAN ASSOCIATION FOR THE STUDY OF
LIVER DISEASES MEETING
    * PXL770 WAS SHOWN TO HAVE A BENEFICIAL EFFECT ON BOTH
ADIPOSE
TISSUE AND LIVER THROUGH DIRECT ACTIVATION OF AMPK IN A DIO-NASH
MODEL
    * PXL065 DATA SUGGESTS POTENTIAL FOR SIMILAR EFFICACY WITH A
REDUCED SIDE EFFECT PROFILE FROM PIOGLITAZONE FOR NASH
    * PXL770 WAS SHOWN TO HAVE A BENEFICIAL EFFECT ON LIVER AND
AT
METABOLISM IN A DIO-NASH MOUSE MODEL
    * PHASE 1 STUDY INDICATED PXL065 WAS SAFE AND
WELL-TOLERATED. NO
ADVERSE EFFECTS WERE REPORTED
    * PXL770 APPEARS TO BE A PROMISING DRUG CANDIDATE FOR
TREATMENT OF
NASH
    * PHASE 1 STUDY INDICATED PXL065 WAS SAFE AND WELL-TOLERATED

Source text for Eikon:  ID:nBw9WZ8W2a 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))